论文部分内容阅读
目的:评价拉米夫定与阿德福韦酯联用对慢性病毒性乙型肝炎患者肝功能和肝纤维化指标的影响。方法:选取2014年3月—2016年3月间收治的慢性病毒性乙型肝炎患者106例病历资料,采用随机分组法将其分为对照组及治疗组,每组53例;对照组患者给予单用拉米夫定治疗,治疗组患者在对照组基础上加用阿德福韦酯治疗,比较两组患者治疗前后的肝功能各指标和肝纤维化各指标的变化情况。结果:两组患者治疗后肝功能与肝纤维各指标测得值均低于治疗前(P<0.05);治疗组患者治疗后的肝功能与肝纤维各指标测得值均低于对照组(P<0.05),完全应答率为54.71%高于对照组为18.87%(P<0.05)。结论:两种抗病毒药物联用治疗慢性病毒性乙型肝炎患者,能够获得较好的临床疗效,可有效改善其肝纤维化与肝功能,完全应答率明显上升。
Objective: To evaluate the effect of combination of lamivudine and adefovir dipivoxil on liver function and liver fibrosis in patients with chronic viral hepatitis B. Methods: A total of 106 patients with chronic viral hepatitis B who were admitted to our hospital from March 2014 to March 2016 were selected and divided into control group and treatment group, with 53 cases in each group. Patients in control group were given single With lamivudine treatment, patients in the treatment group were treated with adefovir dipivoxil on the basis of the control group, and the changes of liver function index and liver fibrosis index before and after treatment were compared between the two groups. Results: The liver function and the indexes of liver fibrosis in both groups were lower than those before treatment (P <0.05). The liver function and the indexes of liver fiber in the treatment group were lower than those in the control group P <0.05). The complete response rate was 54.71% higher than that of the control group (18.87%, P <0.05). Conclusion: The combination of two antiviral drugs in patients with chronic viral hepatitis B can achieve better clinical efficacy, effectively improve liver fibrosis and liver function, and the complete response rate increases significantly.